Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries

Key Points • The life expectancy among Medicare and Medicaid beneficiaries with sickle cell disease was 52.6 years.• Individuals insured by Medicare for disabilities or end-stage renal disease and dually insured by Medicare and Medicaid had worse survival.

• Publication year

  2023

• Venue

  Blood Advances

• Publication date

  2023-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/bloodadvances.2022009202PMID 36929166PMCID 10336259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease

  2022influential reference
• Does Dual-Eligible Medicare/Medicaid Insurance Status as a Surrogate for Socioeconomic Status Compromise Total Knee Arthroplasty Outcomes?

  2022cited by this paper
• Excess death estimates in patients with end-stage renal disease — United States, February–August 2020

  2021cited by this paper
• The Insurance Coverage Paradox - Characterizing Outcomes among Dual-Eligible Hemorrhagic Stroke Patients.

  2021cited by this paper
• Profile of Medicaid enrollees with sickle cell disease: A high need, high cost population

  2021cited by this paper
• Health Disparities Attributed to Medicare-Medicaid Dual-Eligible Status in Patients with Peripheral Arterial Disease.

  2021cited by this paper
• Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers

  2020influential reference
• National Heart, Lung, and Blood Institute

  2020cited by this paper
• Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries

  2020cited by this paper
• Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease

  2020cited by this paper
• Mortality and Hospitalizations for Dually Enrolled and Nondually Enrolled Medicare Beneficiaries Aged 65 Years or Older, 2004 to 2017.

  2020cited by this paper
• Mortality trends in sickle cell patients.

  2020cited by this paper
• Improving an Administrative Case Definition for Longitudinal Surveillance of Sickle Cell Disease

  2019cited by this paper
• Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study

  2019cited by this paper
• Reducing Health Care Disparities in Sickle Cell Disease: A Review

  2019cited by this paper
• United States Life Tables, 2016.

  2019cited by this paper
• Association of Disability With Mortality From Opioid Overdose Among US Medicare Adults

  2019cited by this paper
• Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease

  2019influential reference
• The Effect of Health Care Disparities on Complications and Mortality in Sickle Cell Disease

  2018cited by this paper
• Access to Care for Medicaid and Commercially-Insured United States Patients with Sickle Cell Disease

  2017influential reference
• Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe

  2017cited by this paper
• Sickle cell disease

  2017cited by this paper
• Evolution of sickle cell disease from a life‐threatening disease of children to a chronic disease of adults: The last 40 years

  2016cited by this paper
• Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008

  2016cited by this paper
• A Biopsychosocial Model for the Management of Patients With Sickle-Cell Disease Transitioning to Adult Medical Care

  2015cited by this paper
• Disability Status, Mortality, and Leading Causes of Death in the United States Community Population

  2015cited by this paper
• Disability Stage is an Independent Risk Factor for Mortality in Medicare Beneficiaries Aged 65 Years and Older

  2015cited by this paper
• United States Life Tables

  2013cited by this paper
• Mortality Rates and Age at Death from Sickle Cell Disease: U.S., 1979–2005

  2013cited by this paper
• High one year mortality in adults with sickle cell disease and end‐stage renal disease

  2012cited by this paper
• Hospital volume, hospital teaching status, patient socioeconomic status, and outcomes in patients hospitalized with sickle cell disease

  2011cited by this paper
• Sickle cell disease.

  1996cited by this paper
• Mortality in sickle cell disease. Life expectancy and risk factors for early death.

  1994cited by this paper

• Demystifying Gene-Based Therapies in Pediatric Health Care

  2026cites this paper
• Contemporary Trends, In-Hospital Outcomes, and Adverse Prognosticators of Sickle Cell Patients with Cardiovascular and Thromboembolic Complications: A National Database Analysis.

  2026cites this paper
• Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States.

  2026cites this paper
• Update on Preconception and Pregnancy Management of Sickle Cell Disease

  2026cites this paper
• Curing Sickle Cell Disease by Allogeneic Hematopoietic Stem Cell (HSC) Transplantation Toward In Vivo HSC Gene Therapy

  2025influential citation
• Beyond Childhood: Adult and Adolescent Sickle Cell Disease and Outcomes in Northern Ghana

  2025cites this paper
• Clinical Outcomes Among Patients With Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Literature Review

  2025cites this paper
• An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent β-thalassemia

  2025cites this paper
• Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies.

  2025cites this paper
• Racial Inequities Influencing Admission, Disposition and Hospital Outcomes for Sickle Cell Anemia Patients: Insights from the National Inpatient Sample Database

  2025cites this paper
• Implementing the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Sickle Cell Disease (SCD) - A Case Study.

  2025cites this paper
• Barriers to Care for Adults With Sickle Cell Disease: A Qualitative Descriptive Study

  2025cites this paper
• Complexity within simplicity: Exploring the multifactorial nature of sickle cell disease.

  2025cites this paper
• Comprehensive cardiovascular outcomes in patients with sickle cell disease: real life evidence from a large collaborative network

  2025cites this paper
• Telehealth Use Among Medicaid-Enrolled Children with Sickle Cell Disease Before and During the COVID-19 Pandemic

  2025influential citation
• Factors influencing willingness to utilize the emergency department when experiencing sickle cell disease pain crises.

  2025cites this paper
• Patient Perspectives on Enhancing Clinician Communication About Pain in Sickle Cell Disease

  2025cites this paper
• Sickle cell, thalassemia, and heat: risk estimates and equity policy considerations from an exploratory timeseries study in California

  2025cites this paper
• UHRF2 as a genetic correlate of hospitalization in sickle cell disease

  2025cites this paper
• Ten-Year Longitudinal Study Clarifies Impact of Hemolysis and Pulmonary Hypertension on Patients with Sickle Cell Anemia

  2025cites this paper
• A Case of Atrial Fibrillation and Rapid Ventricular Response in a 22-Year-Old Athlete With Sickle Cell Trait

  2025cites this paper
• Two Approaches for Comparing Characteristics of Decedents With Sickle Cell Disease: Inconsistencies and Implications

  2025cites this paper
• Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020

  2025cites this paper
• Low Use of FDA‐Approved Medications for Sickle Cell Disease in Adults

  2025cites this paper
• The role of religiosity and spirituality in coping with sickle cell disease clinical severity.

  2025cites this paper
• From early development to maturity: a phenotypic analysis of the Townes sickle cell disease mice

  2025cites this paper
• Base editing HbS to HbG-Makassar improves hemoglobin function supporting its use in sickle cell disease

  2025cites this paper
• Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI’s Gene Therapy Access Model

  2025cites this paper
• Selecting patients with sickle cell disease for gene addition or gene editing‐based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference

  2025cites this paper
• Community-engaged research in psychological interventions for pediatric sickle cell disease: a scoping review.

  2025cites this paper
• Stepping Systematically Forward Toward Health Equity in Sickle Cell Disease.

  2024cites this paper
• Homozygous Sickle Cell Disease after Age of 40: Follow-Up of a Cohort of 209 Patients in Senegal, West Africa

  2024cites this paper
• Sickle Cell Disease in an Older Adult Population: A Retrospective Review of Health Care Resource Utilization

  2024cites this paper
• Epigenetic Aging Associations With Psychoneurological Symptoms and Social Functioning in Adults With Sickle Cell Disease

  2024influential citation
• Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States

  2024influential citation
• Electrocardiographic findings in patients with sickle cell disease: A protocol for systematic review and meta‐analysis

  2024cites this paper
• Current and emerging drug treatment strategies to tackle sickle cell anemia

  2024cites this paper
• Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report.

  2024cites this paper
• Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease

  2024cites this paper
• Post‐exchange neutrophil count, but not post‐hematocrit, predicts endogenous erythropoiesis in patients with sickle cell disease undergoing chronic red cell exchange

  2024cites this paper
• Casting light on the national mission to eliminate sickle cell disease in India

  2024cites this paper
• Building capacity for pediatric hematological diseases in Sub-Saharan Africa

  2024cites this paper
• End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care.

  2024cites this paper
• Novel clinical care models for patients with sickle cell disease.

  2024cites this paper
• Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease

  2024cites this paper
• Demographics and outcomes of hemoglobin genotype in hospitalized patients with COVID‐19 and sickle cell disease in the United States

  2023cites this paper
• The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally.

  2023cites this paper
• Mouse models of sickle cell disease: Imperfect and yet very informative.

  2023cites this paper
• Gene therapies for sickle cell disease: Effectiveness and value

  2023cites this paper